Specific transport of temozolomide does not override DNA repair-mediated chemoresistance
Bahrami, K. Kärkkäinen, J. Bibi, Sania Huttunen, J. Tampio, J. Montaser, A.B. Moody, Catherine L. Lehtonen, M. Rautio, J.
Bahrami, K.
Kärkkäinen, J.
Bibi, Sania
Huttunen, J.
Tampio, J.
Montaser, A.B.
Moody, Catherine L.
Lehtonen, M.
Rautio, J.
Publication Date
2024-01-30
End of Embargo
Supervisor
Rights
© 2024 The Authors. Published by Elsevier. This work is distributed under the Creative Commons CC-BY license (https://creativecommons.org/licenses/by/4.0/)
Peer-Reviewed
Yes
Open Access status
openAccess
Accepted for publication
2023-12-03
Institution
Department
Awarded
Embargo end date
Collections
Additional title
Abstract
Temozolomide (TMZ) a DNA alkylating agent, is the standard-of-care for brain tumors, such as glioblastoma multiforme (GBM). Although the physicochemical and pharmacokinetic properties of TMZ, such as chemical stability and the ability to cross the blood-brain barrier (BBB), have been questioned in the past, the acquired chemoresistance has been the main limiting factor of long-term clinical use of TMZ. In the present study, an L-type amino acid transporter 1 (LAT1)-utilizing prodrug of TMZ (TMZ-AA, 6) was prepared and studied for its cellular accumulation and cytotoxic properties in human squamous cell carcinoma, UT-SCC-28 and UT-SCC-42B cells, and TMZ-sensitive human glioma, U-87MG cells that expressed functional LAT1. TMZ-AA 6 accumulated more effectively than TMZ itself into those cancer cells that expressed LAT1 (UT-SCC-42B). However, this did not correlate with decreased viability of treated cells. Indeed, TMZ-AA 6, similarly to TMZ itself, required adjuvant inhibitor(s) of DNA-repair systems, O6-methylguanine-DNA methyl transferase (MGMT) and base excision repair (BER), as well as active DNA mismatch repair (MMR), for maximal growth inhibition. The present study shows that improving the delivery of this widely-used methylating agent is not the main barrier to improved chemotherapy, although utilizing a specific transporter overexpressed at the BBB or glioma cells can have targeting advantages. To obtain a more effective anticancer prodrug, the compound design focus should shift to altering the major DNA alkylation site or inhibiting DNA repair systems.
Version
Published version
Citation
Bahrami K, Kärkkäinen J, Bibi S, et al (2024) Specific Transport of Temozolomide Does not Override DNA Repair-mediated Chemoresistance. European Journal of Pharmaceutical Science. 195: 106661
Link to publisher’s version
Link to published version
Link to Version of Record
Type
Article